Proto360 Health Launches to Help Medical Practices and Employers Standardize GLP-1 Treatment and Metabolic Care

As GLP-1 prescribing outpaces obesity medicine training, Proto360 Health gives physicians across specialties and corporate employers a dedicated care team that starts every patient with the same diagnostic assessment and uses clinical data to guide each phase of treatment.

• Founded by board-certified obesity medicine physicians, Proto360 Health helps medical practices and employers bring a consistent clinical standard and technology infrastructure to GLP-1 and metabolic care.
• Diagnostic insights and metabolic markers guide personalized treatment from day one, with patients moving through each phase of care based on clinical needs and progress.
• Dedicated ProtoMD care teams provide ongoing support throughout treatment, including individualized medication adjustments and treatment planning, while patients stay connected to their own physicians.

ANNAPOLIS, Md., Oct. 27, 2026 /PRNewswire/ -- Proto360 Health, LLC, a metabolic care platform founded by board-certified obesity medicine physicians, launched today to bring a consistent clinical standard to the care surrounding GLP-1 medications, obesity, and metabolic health. Proto360 gives medical practices and employers nationwide a physician-developed protocol, an employed clinical team, and remote monitoring to manage obesity care from the first visit through every stage of treatment.

GLP-1 medications changed obesity treatment faster than the healthcare system built a consistent way to deliver them. Prescriptions come from primary care, specialty practices, and direct-to-consumer telehealth companies, but what happens after the prescription varies widely. For millions of patients, treatment can amount to a single prescription followed by little to no clinical, nutritional, or behavioral support.

A 2025 study published in JAMA Network Open found that nearly two-thirds of patients with overweight or obesity without type 2 diabetes discontinued GLP-1 treatment within one year. Patients who developed moderate or severe gastrointestinal side effects were more likely to stop, and research shows most patients regain significant weight within a year of discontinuation. Proto360's model is built on the view that ongoing clinical support and a plan for every stage of treatment need to be part of metabolic care from the start, including side effect management and guidance when medication needs change.

"Obesity is a chronic disease, and prescribing a GLP-1 or other drug is just one part of treating it," said Dr. Katrina Mattingly, founding partner of Proto360. "Patients need ongoing support to manage side effects, adjust treatment, and plan for what comes next, including when medication needs change. We built Proto360 so practices and employers can give a care team that stays with them well beyond the initial prescription."

Proto360's care model was developed over 10 years of obesity medicine practice. Patients progress through three phases based on clinical benchmarks and individual progress:

• Phase 1 - Starting Treatment: Every Proto360 patient undergoes the same comprehensive diagnostic assessment before treatment begins, including metabolic lab work, body composition measurements, genetic testing, and other health screenings.
• Phase 2 - Care Optimization: Clinicians use that baseline, along with data from body composition scales, continuous glucose monitors, wearables, and periodic labs, to refine medication and lifestyle plans as care progresses.
• Phase 3 - Maintenance and Monitoring: Patients receive ongoing monitoring and individualized medication management, including dose reductions or discontinuation when clinically appropriate.

Care is delivered through ProtoMD, Proto360's medical group, where employed physicians, physician associates, and lifestyle coaches trained on Proto360's protocols manage each patient's evaluation, prescribing, and ongoing care. Patients keep the same care team throughout treatment, and their referring physician stays informed along the way.

"Obesity touches nearly every area of medicine, and most physicians aren't going to become obesity specialists. They need a way to bring in that expertise when a patient needs it," said Dr. John Mulligan, co-founder of Proto360. "We manage the metabolic care, keep the referring physician informed, and return the patient to their practice with a clear plan going forward. Your patients stay your patients."

Proto360 partners with practices across primary care, internal medicine and a range of specialties, including endocrinology, orthopedics, podiatry, plastic surgery, bariatric surgery, OB/GYN and rheumatology, as well as wellness and fitness centers. Proto360 works as a white-labeled extension of the practice, so providers can offer specialized metabolic care without hiring obesity specialists, dietitians, or coaches, writing their own protocols, or building the technology themselves. Patients stay connected to their own physicians throughout care.

The company also works with small and midsize employers. For employers, it pairs GLP-1 coverage with clinical guardrails, continued monitoring, and more predictable costs, so benefits leaders can manage metabolic health as an accountable benefit.

For more information or to join the platform, visit proto360health.com.

About Proto360
Proto360, LLC is a physician-developed metabolic care platform and management services organization that helps medical practices and employers deliver consistent care for obesity and metabolic disease through every phase of treatment. Proto360 combines a physician-developed clinical protocol, employed ProtoMD care teams, diagnostic and metabolic monitoring, and nutrition and lifestyle support. Proto360 operates as a white-labeled extension of the referring practice so patients stay connected to their own physicians. proto360health.com

SOURCE Proto360 Health